Cargando…
Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China
OBJECTIVE: The aim of this study was to describe the clinical features and outcomes of Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHOD: The clinical data and survival statuses of 732 patients with operable HER2-positive breast cancer who were trea...
Autores principales: | Zhou, Ping, Jiang, Yi-Zhou, Hu, Xin, Sun, Wei, Liu, Yi-Rong, Liu, Fang, Luo, Rong-Cheng, Shao, Zhi-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846044/ https://www.ncbi.nlm.nih.gov/pubmed/27143924 http://dx.doi.org/10.2147/OTT.S97583 |
Ejemplares similares
-
Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer
por: Zhao, Shen, et al.
Publicado: (2019) -
A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
por: Zhu, Bo, et al.
Publicado: (2015) -
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022) -
The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis
por: Wu, Yi-Ying, et al.
Publicado: (2016) -
Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
por: Yang, Hai-Yuan, et al.
Publicado: (2017)